Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia
Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U. S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for BNT200, mehr …
www.xn--gtsel-kva.de/content/34124/blue-note-therapeutics-receives-breakthrough-device-designation-for-prescription-only-digital-therapeutic-for-myeloid-leukemia.html
Hope for leukaemia patients through discovery at Karolinska University Hospital
In a recently published study, Nikolas Herold and Martin Jädersten from Karolinska University Hospital show how acute myeloid leukaemia can be treated more effectively. They have reused an already proven medicinal product, mehr …
www.xn--gtsel-kva.de/content/49090/hope-for-leukaemia-patients-through-discovery-at-karolinska-university-hospital.html
Neuer Resistenzmechanismus bei CAR T Zelltherapie entdeckt
Hoffnung auf wirksamere Behandlung bei aggressivem B Zell Lymphom, mehr …
www.xn--gtsel-kva.de/content/105980/neuer-resistenzmechanismus-bei-car-t-zelltherapie-entdeckt.html
